Multicenter survey of the in vitro activity of four expanded-spectrum beta-lactams against consecutive contemporary clinical isolates.
A survey of the in vitro susceptibility of consecutive clinical bacterial isolates to cefotaxime, ceftazidime, cefpodoxime, and aztreonam was conducted at 10 North American medical centers during the first quarter of 1997. All four drugs had good activity against Enterobacteriaceae and fastidious Gram-negative bacteria and poor activity against enterococci and methicillin-resistant staphylococci. No significant trends in susceptibility to cefotaxime or ceftazidime were observed when compared with a previous similar survey. The use of cefpodoxime MIC > 2.0 micrograms/mL as a marker for extended-spectrum beta-lactamase production by Escherichia coli and Klebsiella spp. had good sensitivity, but the specificity was very poor for E. coli. Thus, at least for E. coli, this screening test seems to be of questionable value unless used to indicate the need for additional tests such as clavulanic acid inhibition. Disk diffusion zone diameters correlated well with the MICs for all four drugs and support the current interpretive criteria.